title: Effect of cisplatin on bone transport osteogenesis in dogs.
abstract: OBJECTIVE
  To document effects of cisplatin on regenerate bone formation during the distraction and consolidation phases of bone transport osteogenesis.
  
  
  METHODS
  10 skeletally mature hounds.
  
  
  METHODS
  Bone transport osteogenesis was performed to reconstruct a 3-cm defect in the radius of each dog. Five dogs were randomly selected to receive cisplatin (70 mg/m2, IV, q 21 d for 4 cycles), and 5 were administered saline (0.9% NaCl) solution. Bone mineral density was measured by use of dual-energy x-ray absorptiometry (DEXA) on days 24, 55, and 90 after surgery. Dogs were euthanatized 90 days after surgery. Histomorphometry was performed on nondecalcified sections of regenerate bone. Bone mineral density and histomorphometric indices of newly formed bone were compared between groups.
  
  
  RESULTS
  Densitometric differences in regenerate bone mineral density were not detected between groups at any time period. Cisplatin-treated dogs had decreased mineralized bone volume, decreased percentage of woven bone volume, decreased percentage of osteoblast-covered bone, increased porosity, and increased percentage of osteoblast-covered surfaces, compared with values for control dogs. Lamellar bone volume and osteoid volume did not differ significantly between groups.
  
  
  CONCLUSIONS
  Regenerate bone will form and remodel during administration of cisplatin. Results of histomorphometric analysis suggest that bone formation and resorption may be uncoupled in cisplatin-treated regenerate bone as a result of increased osteoclast activity or delayed secondary bone formation during remodeling. These histomorphometric differences were modest in magnitude and did not result in clinically observable complications or decreased bone mineral density as measured by use of DEXA.
authors.affiliation: Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana 61801, USA.
authors.forename: Nicole
authors.initials: N
authors.lastname: Ehrhart
authors.forename: Jo Ann C
authors.initials: JA
authors.lastname: Eurell
authors.forename: Matteo
authors.initials: M
authors.lastname: Tommasini
authors.forename: Peter D
authors.initials: PD
authors.lastname: Constable
authors.forename: Ann L
authors.initials: AL
authors.lastname: Johnson
authors.forename: Antonio
authors.initials: A
authors.lastname: Feretti
mesh_terms: D015502:Absorptiometry, Photon / Q000662:veterinary; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D015519:Bone Density / Q000502:physiology; D016723:Bone Remodeling / Q000187:drug effects*; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology*; D004285:Dogs / Q000502:physiology*; D016267:External Fixators / Q000662:veterinary; D019857:Osteogenesis, Distraction / Q000379:methods / Q000662:veterinary*; D011884:Radius / Q000033:anatomy & histology / Q000503:physiopathology / Q000601:surgery; D011897:Random Allocation
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin